Conference Coverage

Shingles vaccine protection lasted 5-6 years in autoimmune disease patients


 

FROM THE ACR ANNUAL MEETING

References

Protection against shingles appeared to wane between the fifth and sixth years after patients with autoimmune diseases received the live herpes zoster vaccine, according to a large retrospective cohort study presented at the annual meeting of the American College of Rheumatology.

In contrast, shingles risk remained fairly constant among unvaccinated patients, reported Dr. Huifeng Yun, assistant professor of epidemiology at the University of Alabama, Birmingham. Based on the findings, clinicians could consider revaccinating patients with autoimmune diseases about 5 years after their first live herpes zoster vaccine, she said.*

© clsgraphics/iStockphoto.com

The long-term Shingles Prevention Study recently showed that the live herpes zoster vaccine is effective for about a decade among healthy older individuals, but the duration of protection for patients with autoimmune diseases was unclear, the investigators said. Therefore, they retrospectively studied Medicare data for more than 130,000 such patients between 2006 and 2012. About one-third of patients were vaccinated against herpes zoster, and 47% had rheumatoid arthritis, 32% had psoriasis, 21% had inflammatory bowel disease, 5% had psoriatic arthritis, and 1% had ankylosing spondylitis.

Rates of herpes zoster among vaccinated patients rose from 0.75 per 100 person-years during the first year after vaccination to 1.36 during the sixth year. In the adjusted analysis, vaccinated patients had about half the risk of herpes zoster, compared with unvaccinated patients, during year 1 (relative risk, 0.52; 95% confidence interval, 0.45-0.61) and remained substantially less likely to develop shingles until year 6, when the gap in risk between vaccinated and unvaccinated patients essentially closed (RR, 0.92; 95% CI, 0.45-1.86). There was no overall change in risk among unvaccinated patients during the study period, the investigators noted.

Dr. Yun disclosed a financial relationship with Amgen. The senior author and two coauthors also disclosed relationships with several pharmaceutical companies. Two investigators had no disclosures.

* Correction, 11/13/2015: The article previously misstated Dr. Yun's gender.

rhnews@frontlinemedcom.com

Recommended Reading

Dactylitis warns of future damage in psoriatic arthritis
MDedge Dermatology
Topical calcipotriene-betamethasone combination approved for plaque psoriasis
MDedge Dermatology
Infections from endemic fungi, mycobacteria rare in patients on TNFIs
MDedge Dermatology
EADV: Investigational biologic rocks psoriasis world
MDedge Dermatology
EADV: Ixekizumab promising for psoriatic arthritis
MDedge Dermatology
EADV: Long-term apremilast results show what to expect for psoriasis
MDedge Dermatology
EADV: Spotlight on alexithymia in psoriasis
MDedge Dermatology
EADV: Secukinumab shows sustained high efficacy in SCULPTURE through 3 years
MDedge Dermatology
EADV: No cancer signal with ixekizumab
MDedge Dermatology
Can bariatric surgery ease psoriasis too?
MDedge Dermatology